ALTO NEUROSCIENCE INC (ANRO) — insider trading
Health Care · NYSE
ALTO NEUROSCIENCE INC (ANRO) has 22 reported SEC Form 4 insider transactions in our data, including 3 open-market sales among the most recent 22 (latest 2026-10-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Option exercise / conversion (derivative) | 55,000 | — | $0 | Form 4 |
| 2026-10-02 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Option exercise / conversion | 55,000 | $2.32 | $127.6K | Form 4 |
| 2026-09-30 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Option exercise / conversion (derivative) | 24,056 | — | $0 | Form 4 |
| 2026-09-30 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Open-market sale | 886 | $26.87 | $23.8K | Form 4 |
| 2026-09-30 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Open-market sale | 23,170 | $25.78 | $597.3K | Form 4 |
| 2026-09-30 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Option exercise / conversion | 24,056 | $2.35 | $56.5K | Form 4 |
| 2026-09-29 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Option exercise / conversion (derivative) | 54,375 | — | $0 | Form 4 |
| 2026-09-29 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Option exercise / conversion (derivative) | 56,455 | — | $0 | Form 4 |
| 2026-09-29 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Open-market sale | 110,830 | $26.58 | $2.95M | Form 4 |
| 2026-09-29 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Option exercise / conversion | 54,375 | $2.35 | $127.8K | Form 4 |
| 2026-09-29 | Smith Nicholas Conrad | Officer (PRESIDENT AND CFO) | Option exercise / conversion | 56,455 | $2.35 | $132.7K | Form 4 |
| 2026-05-27 | Miller Andrew Craig | Director | Grant / award / vesting (derivative) | 26,000 | — | $0 | Form 4 |
| 2026-05-14 | Etkin Amit | Director, Officer (PRESIDENT AND CEO) | Bona fide gift | 400,000 | — | $0 | Form 4 |
| 2026-05-12 | York Gwill | Director | Grant / award / vesting (derivative) | 10,958 | — | $0 | Form 4 |
| 2026-05-12 | Dreyfus Andrew | Director | Grant / award / vesting (derivative) | 10,958 | — | $0 | Form 4 |
| 2026-05-12 | Manji Husseini | Director | Grant / award / vesting (derivative) | 10,958 | — | $0 | Form 4 |
| 2026-05-12 | Cox Christopher Nixon | Director | Grant / award / vesting (derivative) | 10,958 | — | $0 | Form 4 |
| 2026-05-12 | Sanchez Ramiro | Director | Grant / award / vesting (derivative) | 10,958 | — | $0 | Form 4 |
| 2026-03-01 | Smith Nicholas Conrad | Officer (CHIEF FINANCIAL OFFICER & CBO) | Shares withheld for taxes / exercise cost | 2,806 | $19.69 | $55.3K | Form 4 |
| 2026-03-01 | Etkin Amit | Director, Officer (PRESIDENT AND CEO) | Shares withheld for taxes / exercise cost | 6,227 | $19.69 | $122.6K | Form 4 |
| 2026-02-11 | Savitz Adam | Officer (CHIEF MEDICAL OFFICER) | Grant / award / vesting (derivative) | 124,000 | — | $0 | Form 4 |
| 2026-02-11 | Etkin Amit | Director, Officer (PRESIDENT AND CEO) | Grant / award / vesting (derivative) | 306,000 | — | $0 | Form 4 |
Ask the chat about ANRO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ALTO NEUROSCIENCE INC (ANRO).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.